Eli Lil­ly R&D chief Jan Lund­berg heads for the ex­it as CEO as­sem­bles a new team at the top

A day af­ter the FDA ap­proved abe­maci­clib, new Eli Lil­ly CEO Dave Ricks has tapped sev­er­al new chiefs for the phar­ma gi­ant’s ex­ec­u­tive com­mit­tee. And the change-out in­cludes the de­par­ture of R&D chief Jan Lund­berg as Ricks pro­motes Dan Skovron­sky as the new head of sci­ence and tech­nol­o­gy and pres­i­dent of Lil­ly Re­search Labs.

Lund­berg has been a cen­tral fig­ure at Lil­ly over the last 8 years, a cru­cial pe­ri­od that saw out the end of John Lech­leit­er’s ca­reer at the top and the be­gin­ning of a stream of new drug ap­provals that are cen­tral to its longterm suc­cess. It hasn’t al­ways been pret­ty, but the R&D group has kept its eyes on chang­ing stan­dards of care in can­cer, di­a­betes and oth­er dis­eases that have seen some big de­vel­op­ments in the re­cent past.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.